

1631 \$

MAILED
JAN 09 2002
JAN 07 2002
OPIE JC152
PATENT AND TRADEMARK OFFICE

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.

November 2, 2001
Date

Sharon Sheridan
Sharon Sheridan

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tongtong Wang and Chaitanya S. Bangur
Application No. : 09/519,642
Filed : March 6, 2000
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF LUNG CANCER

Examiner : M. Borin
Art Unit : 1631
Docket No. : 210121.478C4
Date : November 2, 2001

Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated September 5, 2001, please extend the period of time for response one month, to expire on November 5, 2001. Enclosed are a Petition for an Extension of Time and the requisite fee.

Applicants hereby elect Group II, claim 3, and SEQ ID NO:786, for examination at this time.

Prior to examination on the merits, kindly enter the following amendment:

In the Claims: ✓

Please cancel claim 3.

Please add the following new claims to read as follows:

61. An isolated polypeptide comprising the amino acid sequence of SEQ ID

NO:786.

#100
Zeta
TECH CENTER 1600/2900
JAN 15 2002
RECEIVED

SUB B2
62. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:786, or a fragment thereof comprising at least 10 amino acid residues of SEQ ID NO:786, wherein said fragment binds an antibody having specificity for the polypeptide of SEQ ID NO:786.

63. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:786, or a variant of SEQ ID NO:786 having five or fewer amino acid substitutions, deletions or additions, wherein said variant binds an antibody having specificity for the polypeptide of SEQ ID NO:786.


64. An isolated polypeptide comprising an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO:786.

ai
cencw
65. A composition comprising a polypeptide of any one of claims 61-64 and a physiologically acceptable carrier.

SUB B3
66. A composition comprising a polypeptide of any one of claims 61-64 and a non-specific immune response enhancer.

Please credit any overpayment or charge any deficiency to Deposit Account No. 19-1090. Consideration of the elected claims is now requested.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC


Jeffrey Hundley
Registration No. 42,676

JEH:sds
Enclosure:
Postcard
Check
Petition for an Extension of Time
701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
D:\NrPortbl\iManage\SHARONS\230784_1.DOC